JP6936497B2 - 多価Ｆｖ抗体 - Google Patents

多価Ｆｖ抗体 Download PDF

Info

Publication number
JP6936497B2
JP6936497B2 JP2018519031A JP2018519031A JP6936497B2 JP 6936497 B2 JP6936497 B2 JP 6936497B2 JP 2018519031 A JP2018519031 A JP 2018519031A JP 2018519031 A JP2018519031 A JP 2018519031A JP 6936497 B2 JP6936497 B2 JP 6936497B2
Authority
JP
Japan
Prior art keywords
polypeptide
antigen
variable domains
variable
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018519031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537415A5 (https=
JP2018537415A (ja
Inventor
エルヴァンガー，クリスチナ
フセック，イヴィカ
ロス，トルステン
ミュラー，トーマス
ライコヴィッチ，エーリヒ
ロイシュ，ウーヴェ
トレーダー，マルティン
ヴァイヒェル，ミヒャエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of JP2018537415A publication Critical patent/JP2018537415A/ja
Publication of JP2018537415A5 publication Critical patent/JP2018537415A5/ja
Application granted granted Critical
Publication of JP6936497B2 publication Critical patent/JP6936497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018519031A 2015-10-13 2016-10-13 多価Ｆｖ抗体 Active JP6936497B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15189665.1 2015-10-13
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies
PCT/EP2016/074642 WO2017064221A1 (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Publications (3)

Publication Number Publication Date
JP2018537415A JP2018537415A (ja) 2018-12-20
JP2018537415A5 JP2018537415A5 (https=) 2019-11-21
JP6936497B2 true JP6936497B2 (ja) 2021-09-15

Family

ID=54325413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519031A Active JP6936497B2 (ja) 2015-10-13 2016-10-13 多価Ｆｖ抗体

Country Status (13)

Country Link
US (1) US11572415B2 (https=)
EP (2) EP3156417A1 (https=)
JP (1) JP6936497B2 (https=)
KR (1) KR20180057720A (https=)
CN (1) CN108473577A (https=)
AU (1) AU2016336866B2 (https=)
BR (1) BR112018007445A2 (https=)
CA (1) CA3001765A1 (https=)
IL (1) IL258638B2 (https=)
MX (1) MX2018004547A (https=)
SG (2) SG10202004094VA (https=)
WO (1) WO2017064221A1 (https=)
ZA (1) ZA201802543B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293435B1 (en) 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
BR112020018492A2 (pt) 2018-03-14 2020-12-29 Affimed Gmbh Proteína de ligação ao antígeno egfr/cd16 biespecífica
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
CA3095373A1 (en) * 2018-04-13 2019-10-17 Affimed Gmbh Nk cell engaging antibody fusion constructs
CN112384243A (zh) * 2018-04-17 2021-02-19 英温拉公司 三价三特异性抗体构建体
HRP20240821T1 (hr) 2018-08-27 2024-09-27 Affimed Gmbh Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
JP7592712B2 (ja) * 2019-11-06 2024-12-02 システィミューン， インク． ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
TWI908779B (zh) * 2020-03-17 2025-12-21 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
US20250277024A1 (en) * 2020-12-03 2025-09-04 Amgen Inc. Molecules with multiple binding domains
US20250074996A1 (en) * 2021-02-19 2025-03-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
US20230272069A1 (en) * 2022-02-28 2023-08-31 Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
ATE387458T1 (de) * 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
CA2410551A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
WO2003057829A2 (en) 2001-12-26 2003-07-17 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from vh and vl domains
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US20100150927A1 (en) * 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
DK3725807T3 (da) * 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
WO2014106015A2 (en) 2012-12-28 2014-07-03 Abbvie, Inc. Multivalent binding protein compositions
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
IL293435B1 (en) * 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format

Also Published As

Publication number Publication date
MX2018004547A (es) 2018-11-09
CA3001765A1 (en) 2017-04-20
RU2018126966A (ru) 2020-02-10
EP3362478A1 (en) 2018-08-22
AU2016336866B2 (en) 2023-05-25
US11572415B2 (en) 2023-02-07
IL258638B (en) 2022-12-01
CN108473577A (zh) 2018-08-31
IL258638B2 (en) 2023-04-01
ZA201802543B (en) 2020-01-29
WO2017064221A1 (en) 2017-04-20
BR112018007445A2 (pt) 2019-12-10
KR20180057720A (ko) 2018-05-30
SG10202004094VA (en) 2020-05-28
EP3156417A1 (en) 2017-04-19
IL258638A (en) 2018-06-28
JP2018537415A (ja) 2018-12-20
RU2018126966A3 (https=) 2020-04-20
SG11201803083XA (en) 2018-05-30
AU2016336866A1 (en) 2018-05-10
US20190040155A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
JP6936497B2 (ja) 多価Ｆｖ抗体
US20220048994A1 (en) Trifunctional antigen-binding molecule
EP3875484A1 (en) Cll1-targeting antibody and application thereof
KR102629905B1 (ko) 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
KR20200026995A (ko) 향상된 이중 특이성 폴리펩티드 분자
WO2018177966A1 (en) Improved antigen binding receptors
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
CA3130508A1 (en) Antibody molecules that bind to nkp30 and uses thereof
JP2022553464A (ja) 多重特異性抗体とその製造方法および使用
MX2014000816A (es) Molecula fv de union de antigeno multivalente.
CN115232209A (zh) 靶向gprc5d的抗体及其用途
CN121779568A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
CN112996819B (zh) 细胞分选系统及使用方法
RU2785766C9 (ru) Мультивалентные fv-антитела
RU2785766C2 (ru) Мультивалентные fv-антитела
US20250312453A1 (en) Antibody targeting ccr8 and its applications
HK1260025A1 (en) Multivalent fv antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210820

R150 Certificate of patent or registration of utility model

Ref document number: 6936497

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250